Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver FitzGerald

Showing results (201-210 of 288) with videos related to

Pageof 29
Sort By:
Rheumatology and Therapy|March 30, 2022
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)Georg Schett, Matthew J Loza, Arumugam Palanichamy, et al.
The Journal of Rheumatology|July 9, 2008
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature reviewLaura C Coates, R Rox Anderson, Oliver Fitzgerald, et al.
The Journal of Rheumatology. Supplement|June 3, 2019
The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement SetYing Ying Leung, Ana-Maria Orbai, Alexis Ogdie, et al.
The Journal of Rheumatology|August 13, 2009
Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centersBarry Bresnihan, Eliza Pontifex, Rogier M Thurlings, et al.
Rheumatology and Therapy|July 2, 2022
Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)Georg Schett, Matthew J Loza, Arumugam Palanichamy, et al.
Irish Journal of Medical Science|May 12, 2018
Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelinesKieran E Murray, Louise Moore, Celine O'Brien, et al.
Irish Journal of Medical Science|May 27, 2019
A multidisciplinary approach to reproductive healthcare in women with rheumatic diseaseKieran Murray, Louise Moore, Celine O'Brien, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Arthritis Research & Therapy|December 25, 2013
Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounderEmese Balogh, Joao Madruga Dias, Carl Orr, et al.
Proteomics. Clinical Applications|June 26, 2015
A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritisEmily S Collins, Aisha Q Butt, David S Gibson, et al.
Pageof 29

Showing results (201-210 of 288) with videos related to

Sort By:
Pageof 29
Rheumatology and Therapy|March 30, 2022
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)Georg Schett, Matthew J Loza, Arumugam Palanichamy, et al.
The Journal of Rheumatology|July 9, 2008
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature reviewLaura C Coates, R Rox Anderson, Oliver Fitzgerald, et al.
The Journal of Rheumatology. Supplement|June 3, 2019
The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement SetYing Ying Leung, Ana-Maria Orbai, Alexis Ogdie, et al.
The Journal of Rheumatology|August 13, 2009
Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centersBarry Bresnihan, Eliza Pontifex, Rogier M Thurlings, et al.
Rheumatology and Therapy|July 2, 2022
Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)Georg Schett, Matthew J Loza, Arumugam Palanichamy, et al.
Irish Journal of Medical Science|May 12, 2018
Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelinesKieran E Murray, Louise Moore, Celine O'Brien, et al.
Irish Journal of Medical Science|May 27, 2019
A multidisciplinary approach to reproductive healthcare in women with rheumatic diseaseKieran Murray, Louise Moore, Celine O'Brien, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Arthritis Research & Therapy|December 25, 2013
Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounderEmese Balogh, Joao Madruga Dias, Carl Orr, et al.
Proteomics. Clinical Applications|June 26, 2015
A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritisEmily S Collins, Aisha Q Butt, David S Gibson, et al.
Pageof 29